150 related articles for article (PubMed ID: 30257853)
21. The Importance of a Conjoint Analysis of Tumor-Associated Macrophages and Immune Checkpoints in Pancreatic Cancer.
Xu JY; Wang WS; Zhou J; Liu CY; Shi JL; Lu PH; Ding JL
Pancreas; 2019 Aug; 48(7):904-912. PubMed ID: 31268976
[TBL] [Abstract][Full Text] [Related]
22. Clinical and Biological Significance of PD-L1 Expression Within the Tumor Microenvironment of Oral Squamous Cell Carcinoma.
Takahashi H; Sakakura K; Arisaka Y; Tokue A; Kaira K; Tada H; Higuchi T; Okamoto A; Tsushima Y; Chikamatsu K
Anticancer Res; 2019 Jun; 39(6):3039-3046. PubMed ID: 31177146
[TBL] [Abstract][Full Text] [Related]
23. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA
Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174
[No Abstract] [Full Text] [Related]
24. Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.
Garber ST; Hashimoto Y; Weathers SP; Xiu J; Gatalica Z; Verhaak RG; Zhou S; Fuller GN; Khasraw M; de Groot J; Reddy SK; Spetzler D; Heimberger AB
Neuro Oncol; 2016 Oct; 18(10):1357-66. PubMed ID: 27370400
[TBL] [Abstract][Full Text] [Related]
25. Inflammatory cell infiltrates in advanced metastatic uveal melanoma.
Krishna Y; McCarthy C; Kalirai H; Coupland SE
Hum Pathol; 2017 Aug; 66():159-166. PubMed ID: 28655639
[TBL] [Abstract][Full Text] [Related]
26. Immune subtyping of extranodal NK/T-cell lymphoma: a new biomarker and an immune shift during disease progression.
Cho J; Kim SJ; Park WY; Kim J; Woo J; Kim G; Yoon SE; Ko YH; Kim WS
Mod Pathol; 2020 Apr; 33(4):603-615. PubMed ID: 31653980
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma.
Vassilakopoulou M; Avgeris M; Velcheti V; Kotoula V; Rampias T; Chatzopoulos K; Perisanidis C; Kontos CK; Giotakis AI; Scorilas A; Rimm D; Sasaki C; Fountzilas G; Psyrri A
Clin Cancer Res; 2016 Feb; 22(3):704-13. PubMed ID: 26408403
[TBL] [Abstract][Full Text] [Related]
28. Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma.
Tessier-Cloutier B; Kalloger SE; Al-Kandari M; Milne K; Gao D; Nelson BH; Renouf DJ; Sheffield BS; Schaeffer DF
BMC Cancer; 2017 Sep; 17(1):618. PubMed ID: 28870260
[TBL] [Abstract][Full Text] [Related]
29. Characterizing parathyroid carcinomas and atypical neoplasms based on the expression of programmed death-ligand 1 expression and the presence of tumor-infiltrating lymphocytes and macrophages.
Silva-Figueroa A; Villalobos P; Williams MD; Bassett RL; Clarke CN; Lee JE; Busaidy NL; Perrier ND
Surgery; 2018 Nov; 164(5):960-964. PubMed ID: 30033186
[TBL] [Abstract][Full Text] [Related]
30. Profiling the Tumour Immune Microenvironment in Pancreatic Neuroendocrine Neoplasms with Multispectral Imaging Indicates Distinct Subpopulation Characteristics Concordant with WHO 2017 Classification.
Takahashi D; Kojima M; Suzuki T; Sugimoto M; Kobayashi S; Takahashi S; Konishi M; Gotohda N; Ikeda M; Nakatsura T; Ochiai A; Nagino M
Sci Rep; 2018 Sep; 8(1):13166. PubMed ID: 30177687
[TBL] [Abstract][Full Text] [Related]
31. PD-L1 expression in extrahepatic cholangiocarcinoma.
Walter D; Herrmann E; Schnitzbauer AA; Zeuzem S; Hansmann ML; Peveling-Oberhag J; Hartmann S
Histopathology; 2017 Sep; 71(3):383-392. PubMed ID: 28419539
[TBL] [Abstract][Full Text] [Related]
32. Plasmablastic Lymphomas: Characterization of Tumor Microenvironment Using CD163 and PD-1 Immunohistochemistry.
Ahn JS; Al-Habib A; Vos JA; Sohani AR; Barboza-Quintana O; Flores JP; Wen S; Rosado FG
Ann Clin Lab Sci; 2020 Mar; 50(2):213-218. PubMed ID: 32366559
[TBL] [Abstract][Full Text] [Related]
33. PD-1 and PD-L1 in neoplastic cells and the tumor microenvironment of Merkel cell carcinoma.
Mitteldorf C; Berisha A; Tronnier M; Pfaltz MC; Kempf W
J Cutan Pathol; 2017 Sep; 44(9):740-746. PubMed ID: 28569410
[TBL] [Abstract][Full Text] [Related]
34. Differences in PD-L1-Expressing Macrophages and Immune Microenvironment in Testicular Germ Cell Tumors.
Sadigh S; Farahani SJ; Shah A; Vaughn D; Lal P
Am J Clin Pathol; 2020 Feb; 153(3):387-395. PubMed ID: 31802108
[TBL] [Abstract][Full Text] [Related]
35. PD-L1, PD-1, CD4, and CD8 expression in neoplastic and nonneoplastic thymus.
Marchevsky AM; Walts AE
Hum Pathol; 2017 Feb; 60():16-23. PubMed ID: 27746267
[TBL] [Abstract][Full Text] [Related]
36. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
[TBL] [Abstract][Full Text] [Related]
37. Primary adenocarcinoma of the bladder lacks mismatch repair deficiency and demonstrates PD-L1 expression in tumor-infiltrating immune cells, with implications in both diagnosis and therapeutics.
Jones D; Guan JJ; Calagua C; Hansel DE; Epstein JI; Ye H
Hum Pathol; 2019 Dec; 94():58-63. PubMed ID: 31666198
[TBL] [Abstract][Full Text] [Related]
38. Stage-related PD-L1 expression in Kaposi sarcoma tumor microenvironment.
Joest B; Kempf W; Berisha A; Peyk P; Tronnier M; Mitteldorf C
J Cutan Pathol; 2020 Oct; 47(10):888-895. PubMed ID: 32310306
[TBL] [Abstract][Full Text] [Related]
39. Aligning digital CD8
Conde E; Caminoa A; Dominguez C; Calles A; Walter S; Angulo B; Sánchez E; Alonso M; Jimenez L; Madrigal L; Hernando F; Sanz-Ortega J; Jimenez B; Garrido P; Paz-Ares L; de Castro J; Hernandez S; Lopez-Rios F
Histopathology; 2018 Jan; 72(2):270-284. PubMed ID: 28815764
[TBL] [Abstract][Full Text] [Related]
40. Role of PD-L1 Expression during the Progression of Submucosal Gastric Cancer.
Ubukata Y; Ogata K; Sohda M; Yokobori T; Shimoda Y; Handa T; Nakazawa N; Kimura A; Kogure N; Sano A; Sakai M; Ogawa H; Kuwano H; Shirabe K; Oyama T; Saeki H
Oncology; 2021; 99(1):15-22. PubMed ID: 33113541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
